Gastric cancer advances include HER2-directed therapy, CLDN18.2-targeting, perioperative regimens, and biomarker-informed immunotherapy.
A multicohort analysis of 589,766 adults aged 40 to 74 years without prior cancer, drawn from the Shanghai Men’s Health Study, the Shanghai Women’s Health Study and UK Biobank, estimated how much of the higher cancer incidence in males is attributable to 11 lifestyle factors and health conditions.
The phase 2 portion of ASPEN-06, a randomized, open-label trial, tested whether adding the CD47-blocking fusion protein evorpacept to trastuzumab, ramucirumab and paclitaxel (TRP) improves outcomes in previously treated, HER2-overexpressing advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.
A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.